The Early Onset of Disease May Be a Risk Factor for Decreased Bone Mineral Density in Patients with Inflammatory Bowel Disease
2
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Background/Aims: The pathogenesis of bone loss in patients with inflammatory bowel disease (IBD) is complex, multifactorial, and only partly understood. We aimed to examine the extent and risk factors of bone mass reduction and to analyze the impact of early onset of a disease before attaining peak bone mass in IBD patients. Methods: We compared the risk factors for osteoporosis and BMD at the lumbar spine and the hip bone in IBD patients. Results: A total of 44 patients with IBD were enrolled. Twenty-one and 23 patients were diagnosed as IBD before and after the age of 30and designated as group A and group B, respectively. Group A had significant bone mass reduction at the lumbar spine than group B (BMD, 1.01±0.10 vs. 1.14±0.17, p<0.01; T-score, -1.22±0.84 vs. -0.08±1.39, p<0.01; Z-score, -1.11±0.81 vs. -0.03±1.32, p<0.01, respectively). Multivariate analysis showed that patients diagnosed as IBD before the age of 30 had possible risk factor of bone mass reduction (hazard ratio, 3.96; p=0.06). Conclusions: Bone mass reduction was more severe in patients who were diagnosed with IBD before the age of 30 than in those diagnosed after the age of 30.
Abstract
Background/Aims: The pathogenesis of bone loss in patients with inflammatory bowel disease (IBD) is complex, multifactorial, and only partly understood. We aimed to examine the extent and risk factors of bone mass reduction and to analyze the impact of early onset of a disease before attaining peak bone mass in IBD patients. Methods: We compared the risk factors for osteoporosis and BMD at the lumbar spine and the hip bone in IBD patients. Results: A total of 44 patients with IBD were enrolled. Twenty-one and 23 patients were diagnosed as IBD before and after the age of 30and designated as group A and group B, respectively. Group A had significant bone mass reduction at the lumbar spine than group B (BMD, 1.01±0.10 vs. 1.14±0.17, p<0.01; T-score, -1.22±0.84 vs. -0.08±1.39, p<0.01; Z-score, -1.11±0.81 vs. -0.03±1.32, p<0.01, respectively). Multivariate analysis showed that patients diagnosed as IBD before the age of 30 had possible risk factor of bone mass reduction (hazard ratio, 3.96; p=0.06). Conclusions: Bone mass reduction was more severe in patients who were diagnosed with IBD before the age of 30 than in those diagnosed after the age of 30.
참고문헌 (31)
- Bernstein CN, "Review article: osteoporosis and inflammatory bowel disease", Aliment Pharmacol Ther, 19, pp.941~952 (2004)
- Ali T, "Osteoporosis in inflammatory bowel disease", Am J Med, 122, pp.599~604 (2009)
- Vestergaard P, "Bone loss associated with gastrointestinal disease: prevalence and pathogenesis", Eur J Gastroenterol Hepatol, 15, pp.851~856 (2003)
- Moschen AR, "The RANKL", OPG system is activated in inflammatory bowel disease and relates to the state of bone loss, 2005, pp.54, 479~487
- Miheller P, "Infliximab therapy improves the bone metabolism in fistulizing Crohn’s disease", Dig Dis, 24, pp.201~206 (2006)
- Tenenhouse A, "Estimation of the prevalence of low bone density in Canadian women and men using a populationspecific DXA reference standard: the Canadian Multicentre Osteoporosis Study (CaMos)", Osteoporos Int, 11, pp.897~904 (2000)
- Lofman O, "Bone mineral density in diagnosis of osteoporosis: reference population, definition of peak bone mass, and measured site determine prevalence", J Clin Densitom, 3, pp.177~186 (2000)
- Yang SK, "Epidemiology of inflammatory bowel disease in the Songpa-Kangdong district, Seoul, Korea, 1986-2005: A KASID study", INFLAMMATORY BOWEL DISEASES, 14, pp.542~549 (2008), JOHN WILEY & SONS INC
- Compston JE, "Osteoporosis in patients with inflammatory bowel disease", Gut, 28, pp.410~415 (1987)
- Szathmári M, "Altered bone metabolism in inflammatory bowel disease", Am J Gastroenterol, 93, pp.848~849 (1998)
- Pigot F, "Low bone mineral density in patients with inflammatory bowel disease", Dig Dis Sci, 37, pp.1396~1403 (1992)
- Schulte C, "Reduced bone mineral density and unbalanced bone metabolism in patients with inflammatory bowel disease", Inflamm Bowel Dis, 4, pp.268~275 (1998)
- Schoon EJ, "Osteopenia and osteoporosis in Crohn’s disease: prevalence in a Dutch population-based cohort", Scand J Gastroenterol Suppl, 232, pp.43~47 (2000)
- Robinson RJ, "Osteoporosis and determinants of bone density in patients with Crohn’s disease", Dig Dis Sci, 43, pp.2500~2506 (1998)
- Bernstein CN, "Decreased bone density in inflammatory bowel disease is related to corticosteroid use and not disease diagnosis", J Bone Miner Res, 10, pp.250~256 (1995)
- Bjarnason I, "Reduced bone density in patients with inflammatory bowel disease", Gut, 40, pp.228~233 (1997)
- Bernstein CN, "AGA technical review on osteoporosis in gastrointestinal diseases", Gastroenterology, 124, pp.795~841 (2003)
- Jahnsen J, "Bone mineral density is reduced in patients with Crohn’s disease but not in patients with ulcerative colitis: a population based study", Gut, 40, pp.313~319 (1997)
- Walsh MC, "Osteoimmunology: Interplay between the immune system and bone metabolism", ANNUAL REVIEW OF IMMUNOLOGY, 24, pp.33~63 (2006), ANNUAL REVIEWS
- Henderson S, "A double-blind placebo-controlled study of the effects of the bisphosphonate risedronate on bone mass in patients with inflammatory bowel disease", Am J Gastroenterol, 101, pp.119~123 (2006)
- Oostlander AE, "Histomorphometric analysis reveals reduced bone mass and bone formation in patients with quiescent Crohn’s disease", Gastroenterology, 140, pp.116~123 (2011)
- Ghosh S, "Low bone mineral density in Crohn’s disease, but not in ulcerative colitis, at diagnosis", Gastroenterology, 107, pp.1031~1039 (1994)
- Abitbol V, "Metabolic bone assessment in patients with inflammatory bowel disease", Gastroenterology, 108, pp.417~422 (1995)
- Sonnenberg A, "25-hydroxycholecalciferol serum levels in patients with Crohn’s disease", Acta Hepatogastroenterol (Stuttg), 24, pp.293~295 (1977)
- Driscoll RH Jr, "Vitamin D deficiency and bone disease in patients with Crohn’s disease", Gastroenterology, 83, pp.1252~1258 (1982)
- Compston JE, "Plasma levels and intestinal absorption of 25-hydroxyvitamin D in patients with small bowel resection", Gut, 18, pp.171~175 (1977)
- Soyka LA, "Clinical review 117: hormonal determinants and disorders of peak bone mass in children", J Clin Endocrinol Metab, 85, pp.3951~3963 (2000)
- Kirschner BS, "rowth retardation in inflammatory bowel disease", Gastroenterology, 75, pp.504~511 (1978)
- Griffiths AM, "Growth and clinical course of children with Crohn’s disease", Gut, 34, pp.939~943 (1993)
- Cowan FJ, "Inflammatory bowel disease and predisposition to osteopenia", Arch Dis Child, 76, pp.325~329 (1997)
- Gokhale R, "Bone mineral density assessment in children with inflammatory bowel disease", Gastroenterology, 114, pp.902~911 (1998)